Make clinical management decisions fast with immediate bedside imaging.
Central venous catheter placement and critical procedural guidance.
Now with the new Biplane Imaging™ technology, iQ+ can support critical care clinicians in central venous access, difficult PIV access, arterial access, thora/paracentesis, percutaneous tracheostomy, and airway management. Ultrasound guidance has been shown to improve success rates, reduce the number of attempts, and decrease the complications associated with CVC insertion2.
Focused cardiac assessment.
Does your patient have systolic heart failure? Is there a pericardial effusion? Are they fluid responsive? With 3 dedicated presets for cardiac imaging, Butterfly iQ+ can give you the confidence to make quick bedside decisions in a large range of patient types. Cardiac activity with POCUS has been shown to be the variable most associated with survival after cardiac arrest1.
Lung ultrasound (LUS) can help clinicians rapidly and accurately identify most of the common causes of dyspnea. LUS can also help clinicians identify COVID pneumonia severity and can assist in patient management as well as resource utilization in critical care3.
As iQ+ can be placed in a simple sheath4, it can help preserve PPE as well as eliminate time-consuming cleaning protocols of larger devices. Butterfly iQ+ can also help limit exposure of additional healthcare practitioners by reducing patient transport.
Deep vein thrombosis surveillance.
For patients who have high coagulation, are sedentary for long periods in a critical state, or are being screened for clot pre-CVC insertion, Butterfly iQ+ offers dedicated presets optimized for assisting the clinician to identify DVT. Developed to display echogenic thrombus within deep vessel lumen, iQ+ can support the clinician’s identification of DVT before it develops into a pulmonary embolism.
Recent studies suggest that the prevalence of DVT on admission to a medical-surgical ICU may be as high as 10%, and that the incidence of DVT developing during the ICU stay (based on systematic screening) ranges from 8% to 40%5.